CGP 41 251
N-Benzoylstaurosporine

Tan solid. PROTECT FROM LIGHT. PACKAGED UNDER INERT GAS. A cell-permeable Staurosporine (Cat. No. 569397) derivative that displays antitumor properties. Acts as a broad-spectrum, reversible, and ATP-competitive inhibitor of PKC (a, b and g), PDGFRb, VEGFR2, Syk, PKCh, PKCd, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1, and EGFR (IC₅₀ = 22 nM, 50 nM, 86 nM, 95 nM, 160 nM, 330 nM, 390 nM, 528 nM, 570 nM, 570 nM, 600 nM, 790 nM, 800 nM, 912 nM, and 1.0 µM, respectively). At higher concentrations, also inhibits Ins-R and IGF-1R (IC₅₀ = 10 µM). Shown to potently inhibit the proliferation of Ba/F3 cells expressing constitutively active Flt3 (IC₅₀ < 10 nM). Purity: ≥98% by HPLC. CAS 120685-11-2.

Ref.: Weisberg, E., et al. 2002. Cancer Cell 1, 433. Fabbro, D., et al. 2000. Anticancer Drug Des. 15, 17. Meyer, T., et al. 1999. Int. J. Cancer 81, 669. Meyer, T., et al. 1989. Int. J. Cancer 43, 851.